What does ISO 10993-12 sample preparation mean in practice?
ISO 10993-12 defines the methodological foundation for all biocompatibility-related testing. It determines how samples must be selected, prepared and extracted to ensure realistic, representative and regulator-accepted results. These requirements directly influence the validity and comparability of subsequent endpoints such as cytotoxicity, sensitization, irritation and chemical characterization.
The core aspects include sample strategy (representative portions and worst-case items), handling and preparation (sizing, cleanliness, contamination avoidance) and the use of reference materials and positive/negative controls. These elements ensure comparability and support the scientific robustness of validated systems used downstream.
Extraction is one of the most critical components because it determines which constituents may migrate from a device into contacting media. ISO 10993‑12 requires media, surface-area-to-volume ratio, time and temperature to be selected on a risk basis, always aiming for a realistic worst-case scenario. Properly defined extraction ensures biological and chemical relevance of the resulting data.
Thorough documentation of all parameters – including sample logic, controls, extraction conditions and traceability – is essential for MDR technical files, audit readiness and external toxicological evaluation under ISO 10993‑1.
Norm criteria – at a glance
| Norm criterion | Requirement / content | Note |
|---|---|---|
| Sample strategy | Representative portions / worst case | Clinical relevance |
| Preparation | Sizing, handling, cleanliness | KontaminContamination controlationskontrolle |
| Controls | Reference materials / pos/neg controls | Comparability |
| Extraction | Media, ratio, time, temperature | Endpoint-relevant |
| Documentation | Traceability of parameters | MDR/audit |
How we test your medical device – step by step
- Request a quote by phone or online. Key inputs: device, materials/components, contact type and exposure duration, and the device condition (e.g., sterilized/reprocessed).
- Send your device after accepting the quote. Please provide the sample in the marketed/used state where possible (including reprocessed state if applicable).
- Upon receipt, we start testing and document sample logistics and—where relevant—ISO 10993-12 aligned preparation/extraction parameters.
- We define sample strategy, reference materials/controls and extract preparation according to ISO 10993-12—providing the methodological foundation for downstream tests (e.g., ISO 10993-5/-10/-23) and documentation.
- You receive a digital, QES-signed report with professional interpretation. Upon request, we coordinate next steps through external toxicology (ISO 10993-17) and the ISO 10993-1 Biological Evaluation.
Why HygCen?
- DAkkS accredited testing laboratory (DIN EN ISO/IEC 17025) with GLP-compliant processes.
- Risk-based study design aligned with intended contact type, duration and use.
- Testing in the original state, including relevant processing/sterilization/reprocessing influences.
- Digital, QES-signed report with expert interpretation for MDR technical documentation.
- Methodology first: ISO 10993-12 compliant sample strategy, controls/reference materials and extract preparation as a robust basis for downstream testing and documentation.
ISO 10993‑12 defines how representative samples must be selected, prepared, cleaned and extracted to avoid contamination and reflect realistic worst-case conditions. It also sets requirements for reference materials, positive/negative controls and extraction parameters such as media, surface-area-to-volume ratio and time–temperature profiles. Proper implementation is crucial for reliable results in ISO 10993‑5, 10993‑10, 10993‑23 and analytical studies under ISO 10993‑18.
The chosen sample strategy determines whether relevant risks are correctly identified. Non-representative samples or unrealistic extraction conditions can lead to misinterpretation. Regulatory authorities therefore consider sample strategy a key quality criterion. A well-justified, risk-based approach demonstrates scientific and clinical plausibility.
Reference materials and controls verify test system performance and support interpretation. By eliciting predictable responses, they confirm sensitivity and specificity. ISO 10993‑12 requires appropriate selection and full documentation to ensure reproducibility and audit readiness.
Media, surface-area-to-volume ratio, extraction time and temperature are defined using a risk-based approach. These parameters reflect realistic clinical exposure without introducing artificial over-extraction. All conditions must be justified and fully documented to support regulatory acceptance.
ISO 10993‑12 covers sample preparation for biological assays, whereas ISO 10993‑18 focuses on the analytical identification and quantification of extractables and leachables. Although the goals differ, both standards interact: biological tests often rely on 10993‑12 extracts, while 10993‑18 uses its own analytical extraction procedures. Clear differentiation ensures conceptual consistency.
Related links
ISO 10993-18 – Chemical characterization, ISO 10993-10 – Skin sensitization, ISO 10993-5 – Cytotoxicity, ISO 10993-23 – Irritation, ISO 10993-3 – Genotoxicity, ISO 10993-4 – Hemocompatibility, Pyrogenicity & endotoxin – incl. ISO 10993-11 coordination, ISO 10993-1 – Biological Evaluation